21-Desoxy-9α-fluoro-6α-methyl-prednisolon

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 21-Desoxy-9α-fluoro-6α-methyl-prednisolon
• 英文别名: 6α-Methyl-9α-fluor-11β,17α-dihydroxy-pregna-1,4-dien-3,20-dion；fluorometholone；(6S,9R,10S,11S,13S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₂₂H₂₉FO₄
• 分子量: 376.468
• InChiKey: FAOZLTXFLGPHNG-AAWHYABFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  17α-hydroxy-6α-methyl-9(11)β-epoxy-1,4-pregnadiene-3,20-dione 在 氢氟酸 作用下， 生成 21-Desoxy-9α-fluoro-6α-methyl-prednisolon
  参考文献：
  名称：

  [EN] PROCESS FOR OBTAINING FLUOROMETHOLONE AND INTERMEDIATES THEREFOR
  [FR] PROCÉDÉ POUR L'OBTENTION DE FLUOROMÉTHOLONE ET INTERMÉDIAIRES CORRESPONDANTS

  摘要：

  本发明涉及一种获取化合物的方法，其化学式为（I）和（V），其中R1为C1-C6烷基；R2为OR3，OC(=O)R4或O-(HPG)，其中R3为H，C1-C6烷基或C6-C14芳基；R4为H或C1-C6烷基；HPG为羟基保护基团，用于合成一些类固醇如氟美松及其衍生物的中间体。该发明还涉及其他在合成中有用的中间体。

  公开号：

  WO2010122096A1

文献信息

• Process for obtaining fluorometholone and intermediates therefor
  申请人：Crystal Pharma, S.L.U.

  公开号：EP2246359A1

  公开（公告）日：2010-11-03

  The present invention relates to a process for obtaining compounds of formula (I) and (V), intermediates useful in the synthesis of some steroids, for example, fluorometholone and derivatives thereof. The invention also relates to other intermediates useful in synthesis.

  本发明涉及一种获得式(I)和(V)化合物的工艺，这些化合物是用于合成某些类固醇，如氟甲孕酮及其衍生物的中间体。本发明还涉及其他用于合成的中间体。
• Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions
  申请人：Potter Jeffrey A.

  公开号：US20080275015A1

  公开（公告）日：2008-11-06

  The invention of this application relates to a formulation and method of using the formulation for the treatment of interstitial cystitis and other similar conditions of the bladder. The formulation of this invention is a highly specialized, compounded pharmaceutical that contains a combination of numerous therapeutically different medications in a unique delivery vehicle and system. The individual components of the formulation work synergistically to restore and repair each of the different issues associated with interstitial cystitis. The individual components of the formulation exist in an aqueous vehicle to facilitate drug contact with the bladder wall. The formulation is instilled directly into the bladder, commonly in a physician's office.